|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GNA15 |
Gene summary for GNA15 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GNA15 | Gene ID | 2769 |
| Gene name | G protein subunit alpha 15 | |
| Gene Alias | GNA16 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | P30679 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2769 | GNA15 | C46 | Human | Oral cavity | OSCC | 6.66e-23 | 6.64e-01 | 0.1673 |
| 2769 | GNA15 | C51 | Human | Oral cavity | OSCC | 1.36e-34 | 1.51e+00 | 0.2674 |
| 2769 | GNA15 | C57 | Human | Oral cavity | OSCC | 5.65e-41 | 1.27e+00 | 0.1679 |
| 2769 | GNA15 | C06 | Human | Oral cavity | OSCC | 6.76e-11 | 1.53e+00 | 0.2699 |
| 2769 | GNA15 | C07 | Human | Oral cavity | OSCC | 1.11e-04 | 1.38e+00 | 0.2491 |
| 2769 | GNA15 | C08 | Human | Oral cavity | OSCC | 5.03e-36 | 8.37e-01 | 0.1919 |
| 2769 | GNA15 | C09 | Human | Oral cavity | OSCC | 2.76e-05 | 2.63e-01 | 0.1431 |
| 2769 | GNA15 | LN22 | Human | Oral cavity | OSCC | 8.32e-14 | 1.34e+00 | 0.1733 |
| 2769 | GNA15 | LN38 | Human | Oral cavity | OSCC | 5.08e-03 | 7.91e-01 | 0.168 |
| 2769 | GNA15 | LN46 | Human | Oral cavity | OSCC | 3.70e-15 | 6.51e-01 | 0.1666 |
| 2769 | GNA15 | LP15 | Human | Oral cavity | LP | 4.96e-07 | 1.25e+00 | 0.2174 |
| 2769 | GNA15 | LP17 | Human | Oral cavity | LP | 4.17e-05 | 6.21e-01 | 0.2349 |
| 2769 | GNA15 | EOLP-1 | Human | Oral cavity | EOLP | 1.10e-12 | 5.64e-01 | -0.0202 |
| 2769 | GNA15 | EOLP-2 | Human | Oral cavity | EOLP | 2.08e-03 | 2.86e-01 | -0.0203 |
| 2769 | GNA15 | SYSMH1 | Human | Oral cavity | OSCC | 2.05e-20 | 5.53e-01 | 0.1127 |
| 2769 | GNA15 | SYSMH2 | Human | Oral cavity | OSCC | 1.60e-16 | 5.78e-01 | 0.2326 |
| 2769 | GNA15 | SYSMH3 | Human | Oral cavity | OSCC | 1.46e-33 | 8.74e-01 | 0.2442 |
| 2769 | GNA15 | SYSMH5 | Human | Oral cavity | OSCC | 1.28e-09 | 3.78e-01 | 0.0647 |
| 2769 | GNA15 | SYSMH6 | Human | Oral cavity | OSCC | 4.07e-02 | 2.30e-01 | 0.1275 |
| 2769 | GNA15 | P4_S8_cSCC | Human | Skin | cSCC | 1.96e-04 | 2.62e-01 | -0.3095 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00725032 | Oral cavity | EOLP | cellular divalent inorganic cation homeostasis | 75/2218 | 486/18723 | 9.77e-03 | 4.42e-02 | 75 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa049268 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
| hsa051425 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
| hsa0492616 | Esophagus | ESCC | Relaxin signaling pathway | 81/4205 | 129/8465 | 1.72e-03 | 5.09e-03 | 2.61e-03 | 81 |
| hsa0514213 | Esophagus | ESCC | Chagas disease | 65/4205 | 102/8465 | 2.81e-03 | 7.59e-03 | 3.89e-03 | 65 |
| hsa051424 | Oral cavity | OSCC | Chagas disease | 64/3704 | 102/8465 | 8.00e-05 | 2.95e-04 | 1.50e-04 | 64 |
| hsa049267 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
| hsa051468 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| hsa0514212 | Oral cavity | OSCC | Chagas disease | 64/3704 | 102/8465 | 8.00e-05 | 2.95e-04 | 1.50e-04 | 64 |
| hsa0492615 | Oral cavity | OSCC | Relaxin signaling pathway | 74/3704 | 129/8465 | 1.20e-03 | 3.37e-03 | 1.72e-03 | 74 |
| hsa0514615 | Oral cavity | OSCC | Amoebiasis | 59/3704 | 102/8465 | 2.78e-03 | 7.17e-03 | 3.65e-03 | 59 |
| hsa0514221 | Oral cavity | EOLP | Chagas disease | 28/1218 | 102/8465 | 4.05e-04 | 1.64e-03 | 9.65e-04 | 28 |
| hsa0514623 | Oral cavity | EOLP | Amoebiasis | 26/1218 | 102/8465 | 2.09e-03 | 7.03e-03 | 4.15e-03 | 26 |
| hsa0492622 | Oral cavity | EOLP | Relaxin signaling pathway | 30/1218 | 129/8465 | 4.48e-03 | 1.42e-02 | 8.37e-03 | 30 |
| hsa051423 | Oral cavity | EOLP | Chagas disease | 28/1218 | 102/8465 | 4.05e-04 | 1.64e-03 | 9.65e-04 | 28 |
| hsa0514633 | Oral cavity | EOLP | Amoebiasis | 26/1218 | 102/8465 | 2.09e-03 | 7.03e-03 | 4.15e-03 | 26 |
| hsa0492631 | Oral cavity | EOLP | Relaxin signaling pathway | 30/1218 | 129/8465 | 4.48e-03 | 1.42e-02 | 8.37e-03 | 30 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GNA15 | SNV | Missense_Mutation | c.982N>A | p.Glu328Lys | p.E328K | P30679 | protein_coding | deleterious(0.04) | benign(0) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
| GNA15 | deletion | Frame_Shift_Del | novel | c.832delN | p.Thr279ProfsTer171 | p.T279Pfs*171 | P30679 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| GNA15 | deletion | Frame_Shift_Del | novel | c.354delN | p.Gln119ArgfsTer6 | p.Q119Rfs*6 | P30679 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| GNA15 | SNV | Missense_Mutation | rs760016259 | c.766N>A | p.Ala256Thr | p.A256T | P30679 | protein_coding | tolerated(0.28) | probably_damaging(0.937) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GNA15 | SNV | Missense_Mutation | c.788N>G | p.Glu263Gly | p.E263G | P30679 | protein_coding | tolerated(0.17) | possibly_damaging(0.503) | TCGA-EK-A2PI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GNA15 | SNV | Missense_Mutation | c.982N>A | p.Glu328Lys | p.E328K | P30679 | protein_coding | deleterious(0.04) | benign(0) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GNA15 | SNV | Missense_Mutation | c.927N>C | p.Lys309Asn | p.K309N | P30679 | protein_coding | tolerated(0.07) | possibly_damaging(0.767) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| GNA15 | SNV | Missense_Mutation | rs760016259 | c.766N>A | p.Ala256Thr | p.A256T | P30679 | protein_coding | tolerated(0.28) | probably_damaging(0.937) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| GNA15 | SNV | Missense_Mutation | rs151214875 | c.595N>A | p.Val199Met | p.V199M | P30679 | protein_coding | tolerated(0.25) | possibly_damaging(0.596) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GNA15 | SNV | Missense_Mutation | c.982G>A | p.Glu328Lys | p.E328K | P30679 | protein_coding | deleterious(0.04) | benign(0) | TCGA-UC-A7PG-06 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |